3-year update on the eloquent-2 clinical trial of elotuzumab in multiple myeloma
Published 8 years ago • 64 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
2:19
update on eloquent-2: phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
-
1:41
eloquent-2 trial of elotuzumab plus lenalidomide/dexamethasone in multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:00
results of eloquent-2 trial for treatment multiple myeloma
-
0:36
the potential of immunotherapies in the myeloma treatment landscape
-
3:15
what is the best diet for myeloma patients to build a strong immune system?
-
2:23
dr. socinski on why you should attend winter lung cancer conference
-
24:46
sumit verma of iovance biotherapeutics - 1 time therapy for solid tumors
-
3:59
3-year follow-up from the transform trial: liso-cel is superior to soc in r/r dlbcl
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
1:53
the future of multiple myeloma treatment
-
1:47
real-world outcomes of tandem transplantation in patients with newly diagnosed multiple myeloma
-
2:33
an update on antibody-based treatment approaches in multiple myeloma
-
2:30
a new era of treatment for multiple myeloma
-
5:22
updates on german clinical trials in multiple myeloma
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
2:10
phase ii study of epd maintenance after second autologous transplant for multiple myeloma
-
2:36
a multi-omic study to improve the diagnosis of multiple myeloma
-
2:44
novel bcma-targeting therapies to treat tce relapsed/refractory multiple myeloma
-
1:54
the future of multiple myeloma treatment
-
1:25
cartitude-1: outcomes of patients with triple-class exposed multiple myeloma treated with cilta-cel
-
1:30
exploring the role of upfront autosct in multiple myeloma